Ribo Life Science: An application for a Phase I clinical trial of RBD3133 injection for the treatment of overweight and obesity has been submitted in the European Union.

On the morning of October 8, Ribo Life Science announced on the Hong Kong Stock Exchange that it has submitted an application in the European Union for a Phase I clinical trial of RBD3133 injection, a siRNA product targeting INHBE, for the treatment indication of overweight and obesity. RBD3133 injection is designed to selectively silence INHBE. Human genetics studies have shown that individuals carrying naturally occurring loss-of-function variants in INHBE have healthier fat distribution, improved metabolic profiles, and a lower predicted risk of coronary heart disease and type 2 diabetes. These findings support INHBE as a highly promising therapeutic target for the treatment of obesity and related metabolic diseases.